Company Shares of Eli Lilly and Company Drops by -0.12%

Eli Lilly and Company (NYSE:LLY) has tumbled 0.12% during the past week and has dropped 1.27% in the last 4 week period. The company has outperformed the S&P 500 by 1.08% in the past week but underperformed the index by 2.17% in the last 4 weeks.

Eli Lilly and Company (NYSE:LLY): The stock opened at $74.65 on Friday but the bulls could not build on the opening and the stock topped out at $75.08 for the day. The stock traded down to $73.48 during the day, due to lack of any buying support eventually closed down at $73.86 with a loss of -0.53% for the day. The stock had closed at $74.25 on the previous day. The total traded volume was 6,604,924 shares.

The company shares have dropped -10.61% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $92.85 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $75.23 and the 200 Day Moving Average price is recorded at $77.13.

On the companys insider trading activities, Barnes Melissa S, officer (Chief Eth/Cmpl Ofcr & SVP, ERM) of Lilly Eli & Co, unloaded 992 shares at an average price of $73.77 on June 10, 2016. The total amount of the transaction was worth $73,180, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Many analysts have stated their opinion on the company shares. In the latest statement by the brokerage house, Leerink Swann maintains its outlook on Eli Lilly and Company (NYSE:LLY). The current rating of the shares is Outperform, according to the research report released by the firm. The brokerage firm raises the price target from $96 per share to $101 per share. The rating by the firm was issued on May 2, 2016. Currently the company Insiders own 0.2% of Eli Lilly and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.61% . Institutional Investors own 76.21% of Eli Lilly and Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.63%.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Leave a Reply

Janet Gordon - Is it time to Sell?

Top Brokerage Firms are advising their investors on Janet Gordon. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.